Axim Biotechnologies Inc (AXIM)

[Devolution]

Personally I don't believe that the military actions in the Ukraine are affecting Axim's pps to any great extent.

More likely it is the loss of hope of an EUA that will be keeping the pps down for the next few months.

The light at the end of the tunnel should be sales of the DED line and sales of the Nabs assay test kits for Research Use Only, both of which won't be visible until the 2nd quarter 10-Q, due out on August 15th (5 months from now).

Quite a long wait (5 months) for anyone who was hoping for a nice pop in the near future, but I still believe it will prove worthwhile in the end.

Behind the scenes, great things are happening at Axim:

1. There are 2 DED test kits going to market soon (for use as diagnostic tools by medical professionals, ie: ophthalmologists)

2. The Nabs tests have been redirected to being marketed to the research market, which is where Axim's Nab test should prove extremely useful, as the test kits are very accurate and give immediate results. This at a time when the entire world is anxious to discover how effective natural immunity is, how the different vaccinations, combinations, and number of shots given effect immunity, how long immunity lasts, and how any combination of all of these factors as well as others have been on the creation of Nabs - and what those Nabs levels translate into. There is a hell of a lot of research work to be done, and Axim's test kits are ideal for helping research much more rapidly come to their results and sort this all out.

3. Axim has not given up the idea of using its Nabs test kits in medical fields and/or the retail market

While AXIM explores filing one or more EUA ’s for point of care and/or at home use, AXIM has determined that the NAb test would be a valuable tool to offer For Research Use Only.

4. There is a 3rd DED test kit, just developed, that Axim is now seeking FDA 510(k) approval for, and as this diagnostic test kit is just a superior version (ie: IMMEDIATE in-office results) from those that are already approved, the process should move fairly quickly, and this test kit could easily join the other two DED line test kits prior to the end of this year.

5. Axim also has its extremely promising cancer related research going on which should prove to be quite useful in years to come.

Think of 1-4 like planting seeds in the Spring, and the harvest (results) won't come till the late Fall. Similarly, #5 above is like planting a seed for a fruit tree.

I'm still going to hold to my predictions for Axim by year end, even with the delay in sales of the DED line test kits till the 2nd Quarter, but with the addition of the Nabs RUO sales and the potential 4th quarter addition of the newest DED test kit to the market.

If you find yourself disappointed (as I do) by the lack of an EUA for "Immunopass", just imagine how disappointed John H and the rest of those at Axim feel.

It is a good thing, though, that they don't let disappointment hold them back.

Godspeed to all involved here.